title: Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison.
abstract: JG-03-14, a substituted pyrrole that inhibits microtubule polymerization, was screened against MCF-7 (p53 wild type), MDA-MB231 (p53 mutant), MCF-7/caspase 3 and MCF-7/ADR (multidrug resistant) breast tumor cell lines. Cell viability and growth inhibition were assessed by the crystal violet dye assay. Apoptosis was evaluated by the TUNEL assay, cell cycle distribution by flow cytometry, autophagy by acridine orange staining of vesicle formation, and senescence based on beta-galactosidase staining and cell morphology. Our studies indicate that exposure to JG-03-14, at a concentration of 500 nM, induces time-dependent cell death in the MCF-7 and MDA-MB231 cell lines. In MCF-7 cells, a residual surviving cell population was found to be senescent; in contrast, there was no surviving senescent population in treated MDA-MB231 cells. No proliferative recovery was detected over a period of 15 days post-treatment in either cell line. Both the TUNEL assay and FLOW cytometry indicated a relatively limited degree of apoptosis (<10%) in response to drug treatment in MCF-7 cells with more extensive apoptosis (but <20%) in MDA-MB231 cells; acidic vacuole formation indicative of autophagic cell death was relatively extensive in both MCF-7 and MDA-MB231 cells. In addition, JG-03-14 induced the formation of a large hyperdiploid cell population in MDA-MB231 cells. JG-03-14 also demonstrated pronounced anti-proliferative activity in MCF-7/caspase 3 cells and in the MCF-7/ADR cell line. The observation that JG-03-14 promotes autophagic cell death and also retains activity in tumor cells expressing the multidrug resistance pump indicates that novel microtubule poisons of the substituted pyrroles class may hold promise in the treatment of breast cancer.
authors: Department of Pharmacology and Toxicology and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
authors: Christopher R
authors: CR
authors: Arthur
authors: John T
authors: JT
authors: Gupton
authors: Glen E
authors: GE
authors: Kellogg
authors: W Andrew
authors: WA
authors: Yeudall
authors: Myles C
authors: MC
authors: Cabot
authors: Irene F
authors: IF
authors: Newsham
authors: David A
authors: DA
authors: Gewirtz
mesh_terms: D000375:Aging / Q000187:drug effects; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001343:Autophagy / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D053148:Caspase 3 / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002869:Chromosome Aberrations; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008870:Microtubules / Q000187:drug effects; D015394:Molecular Structure; D011123:Polyploidy; D011758:Pyrroles / Q000737:chemistry / Q000494:pharmacology*; D013997:Time Factors
chemical_list: C521391:3,5-dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid ethyl ester; D000970:Antineoplastic Agents; D011758:Pyrroles; D053148:Caspase 3
references: Cancer Lett. 2007 Jan 8;245(1-2):350-2
references: 16504380
references: Genes Dev. 2006 Oct 1;20(19):2687-700
references: 17015431
references: Arch Pharm (Weinheim). 2000 Jan;333(1):3-9
references: 10675983
references: Cancer Res. 2001 Jan 1;61(1):348-54
references: 11196185
references: Cancer Res. 2001 Jan 15;61(2):439-44
references: 11212227
references: J Biol Chem. 2002 Sep 20;277(38):35509-15
references: 12101184
references: Oncogene. 2002 Dec 12;21(57):8843-51
references: 12483536
references: Arch Pharm (Weinheim). 2003 Jun;336(3):181-90
references: 12822184
references: J Cell Sci. 2004 Apr 1;117(Pt 9):1757-71
references: 15075237
references: Biochim Biophys Acta. 1976 Nov 11;455(1):152-62
references: 990323
references: J Biol Chem. 1986 Nov 25;261(33):15544-9
references: 3782078
references: J Biol Chem. 1990 Jun 15;265(17):10073-80
references: 1972154
references: J Cell Biol. 1992 Nov;119(3):493-501
references: 1400587
references: Int J Cancer. 1993 Jan 21;53(2):290-7
references: 8425767
references: Cell. 1993 Sep 24;74(6):957-67
references: 8402885
references: Cell Growth Differ. 1994 Jul;5(7):723-33
references: 7947387
references: Science. 1994 Nov 4;266(5186):807-10
references: 7973635
references: Science. 1995 Mar 3;267(5202):1353-6
references: 7871434
references: Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
references: 7568133
references: Biochem Pharmacol. 1996 Apr 12;51(7):931-40
references: 8651943
references: Cancer Res. 1996 Feb 15;56(4):892-8
references: 8631030
references: Cancer. 1996 Sep 15;78(6):1203-10
references: 8826941
references: Mol Cancer Ther. 2006 Nov;5(11):2786-97
references: 17121925
references: Mol Pharmacol. 1996 Dec;50(6):1536-40
references: 8967975
references: Br J Cancer. 1998;77(3):404-11
references: 9472635
references: Mutagenesis. 1998 Mar;13(2):193-8
references: 9568594
references: Exp Cell Res. 1998 May 25;241(1):96-101
references: 9633517
references: Oncogene. 1998 Nov 26;17(21):2743-51
references: 9840938
references: Oncol Rep. 1999 Jan-Feb;6(1):33-7
references: 9864397
references: Arch Pharm (Weinheim). 1998 Nov;331(11):337-41
references: 9881055
references: Cancer Res. 1999 Apr 1;59(7):1626-34
references: 10197639
references: Cancer Res. 1999 Aug 1;59(15):3831-7
references: 10447002
references: Pharmazie. 1999 Sep;54(9):691-7
references: 10522273
references: J Steroid Biochem Mol Biol. 2004 Dec;92(5):365-74
references: 15698541
references: Clin Cancer Res. 2005 Apr 1;11(7):2637-43
references: 15814644
references: Cell Cycle. 2005 Mar;4(3):501-7
references: 15711127
references: Int J Radiat Biol. 2005 Jun;81(6):445-58
references: 16308915
references: Autophagy. 2005 Oct-Dec;1(3):171-3
references: 16874039
references: Mol Pharmacol. 2007 Jul;72(1):132-40
references: 17456786